Pfizer Inc Stock Book Value Per Share

PFE Stock

USD 25.91 0.05 0.19%

Pfizer Inc fundamentals help investors to digest information that contributes to Pfizer's financial success or failures. It also enables traders to predict the movement of Pfizer Stock. The fundamental analysis module provides a way to measure Pfizer's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pfizer stock.

	Last Reported	Projected for Next Year
Book Value Per Share	15.77	16.56
Tangible Book Value Per Share	(7.69)	(7.31)

The current year's Book Value Per Share is expected to grow to 16.56, whereas Tangible Book Value Per Share is projected to grow to (7.31).

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Pfizer Inc Company Book Value Per Share Analysis

Pfizer's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Book Value per Share

Common Equity

Average Shares

More About Book Value Per Share | All Equity Analysis

Current Pfizer Book Value Per Share

15.77 X

Most of Pfizer's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pfizer Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Pfizer Book Value Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Pfizer is extremely important. It helps to project a fair market value of Pfizer Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Pfizer's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pfizer's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pfizer's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Property Plant Equipment	Accounts Payable	Short Term Investments	Common Stock	Long Term Debt	Good Will	Treasury Stock	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.77	0.82	0.77	0.54	0.98	0.64	0.35	0.87	0.84	0.87	0.3	0.91	0.88	0.79	-0.61	0.32	0.44	0.48	0.06	0.54	-0.28	0.08	0.21	-0.14	0.45	-0.36	-0.4
Total Stockholder Equity	0.77		0.37	0.55	0.72	0.68	0.86	0.21	0.55	0.92	0.62	0.59	0.81	0.48	0.78	-0.43	0.26	0.29	0.27	-0.07	0.34	-0.15	0.09	-0.04	-0.17	0.28	0.01	0.2
Net Debt	0.82	0.37		0.79	0.11	0.88	0.15	0.51	0.81	0.58	0.8	-0.19	0.68	0.96	0.68	-0.7	0.23	0.46	0.62	0.42	0.68	-0.47	0.06	0.55	-0.13	0.62	-0.7	-0.59
Retained Earnings	0.77	0.55	0.79		0.13	0.76	0.28	0.28	0.54	0.63	0.92	0.01	0.78	0.8	0.73	-0.95	0.15	0.68	0.64	0.21	0.93	-0.68	0.24	0.32	-0.54	0.46	-0.41	-0.47
Net Receivables	0.54	0.72	0.11	0.13		0.46	0.73	0.05	0.41	0.72	0.35	0.42	0.52	0.25	0.46	0.01	0.39	0.04	0.27	-0.23	-0.08	-0.01	-0.05	-0.14	-0.04	-0.04	0.16	0.16
Total Liab	0.98	0.68	0.88	0.76	0.46		0.55	0.46	0.89	0.8	0.84	0.2	0.9	0.91	0.81	-0.64	0.38	0.38	0.5	0.1	0.56	-0.25	0.05	0.33	-0.08	0.45	-0.42	-0.42
Total Current Assets	0.64	0.86	0.15	0.28	0.73	0.55		0.03	0.38	0.71	0.38	0.85	0.7	0.29	0.53	-0.17	0.3	0.09	0.0	-0.35	0.04	0.11	0.03	-0.28	0.02	-0.03	0.33	0.2
Short Term Debt	0.35	0.21	0.51	0.28	0.05	0.46	0.03		0.43	0.37	0.2	-0.21	0.43	0.32	0.65	-0.37	0.48	-0.39	0.18	0.04	0.25	0.03	-0.18	0.86	-0.09	0.18	-0.45	0.15
Intangible Assets	0.87	0.55	0.81	0.54	0.41	0.89	0.38	0.43		0.67	0.73	0.05	0.68	0.82	0.64	-0.36	0.24	0.24	0.45	0.18	0.32	-0.11	-0.23	0.35	0.05	0.56	-0.49	-0.42
Property Plant Equipment	0.84	0.92	0.58	0.63	0.72	0.8	0.71	0.37	0.67		0.72	0.33	0.87	0.65	0.9	-0.55	0.39	0.31	0.51	0.09	0.47	-0.26	0.04	0.18	-0.16	0.35	-0.15	0.08
Accounts Payable	0.87	0.62	0.8	0.92	0.35	0.84	0.38	0.2	0.73	0.72		0.04	0.76	0.86	0.71	-0.78	0.07	0.69	0.69	0.26	0.8	-0.62	0.07	0.26	-0.41	0.58	-0.38	-0.51
Short Term Investments	0.3	0.59	-0.19	0.01	0.42	0.2	0.85	-0.21	0.05	0.33	0.04		0.39	-0.07	0.16	0.06	0.06	-0.06	-0.31	-0.54	-0.17	0.33	0.08	-0.5	0.1	-0.23	0.55	0.29
Common Stock	0.91	0.81	0.68	0.78	0.52	0.9	0.7	0.43	0.68	0.87	0.76	0.39		0.72	0.9	-0.73	0.57	0.28	0.46	-0.16	0.59	-0.25	0.08	0.24	-0.28	0.15	-0.15	-0.17
Long Term Debt	0.88	0.48	0.96	0.8	0.25	0.91	0.29	0.32	0.82	0.65	0.86	-0.07	0.72		0.67	-0.67	0.21	0.59	0.61	0.42	0.65	-0.49	0.14	0.35	-0.08	0.61	-0.61	-0.62
Good Will	0.79	0.78	0.68	0.73	0.46	0.81	0.53	0.65	0.64	0.9	0.71	0.16	0.9	0.67		-0.73	0.51	0.17	0.54	0.09	0.63	-0.31	-0.03	0.5	-0.27	0.3	-0.24	0.07
Treasury Stock	-0.61	-0.43	-0.7	-0.95	0.01	-0.64	-0.17	-0.37	-0.36	-0.55	-0.78	0.06	-0.73	-0.67	-0.73		-0.25	-0.54	-0.62	-0.17	-0.97	0.65	-0.24	-0.42	0.56	-0.3	0.32	0.33
Current Deferred Revenue	0.32	0.26	0.23	0.15	0.39	0.38	0.3	0.48	0.24	0.39	0.07	0.06	0.57	0.21	0.51	-0.25		-0.37	0.21	-0.44	0.06	0.08	-0.15	0.31	-0.17	-0.52	0.05	0.08
Net Tangible Assets	0.44	0.29	0.46	0.68	0.04	0.38	0.09	-0.39	0.24	0.31	0.69	-0.06	0.28	0.59	0.17	-0.54	-0.37		0.43	0.49	0.66	-0.66	0.49	-0.24	-0.23	0.58	-0.34	-0.58
Total Permanent Equity	0.48	0.27	0.62	0.64	0.27	0.5	0.0	0.18	0.45	0.51	0.69	-0.31	0.46	0.61	0.54	-0.62	0.21	0.43		0.36	0.67	-0.73	-0.16	0.46	-0.51	0.3	-0.32	-0.37
Long Term Debt Total	0.06	-0.07	0.42	0.21	-0.23	0.1	-0.35	0.04	0.18	0.09	0.26	-0.54	-0.16	0.42	0.09	-0.17	-0.44	0.49	0.36		0.33	-0.47	0.14	0.26	0.21	0.77	-0.58	-0.19
Capital Surpluse	0.54	0.34	0.68	0.93	-0.08	0.56	0.04	0.25	0.32	0.47	0.8	-0.17	0.59	0.65	0.63	-0.97	0.06	0.66	0.67	0.33		-0.75	0.24	0.39	-0.56	0.42	-0.36	-0.38
Deferred Long Term Liab	-0.28	-0.15	-0.47	-0.68	-0.01	-0.25	0.11	0.03	-0.11	-0.26	-0.62	0.33	-0.25	-0.49	-0.31	0.65	0.08	-0.66	-0.73	-0.47	-0.75		-0.15	-0.26	0.66	-0.35	0.31	0.41
Long Term Investments	0.08	0.09	0.06	0.24	-0.05	0.05	0.03	-0.18	-0.23	0.04	0.07	0.08	0.08	0.14	-0.03	-0.24	-0.15	0.49	-0.16	0.14	0.24	-0.15		-0.25	0.07	0.13	-0.33	-0.16
Short Long Term Debt	0.21	-0.04	0.55	0.32	-0.14	0.33	-0.28	0.86	0.35	0.18	0.26	-0.5	0.24	0.35	0.5	-0.42	0.31	-0.24	0.46	0.26	0.39	-0.26	-0.25		-0.28	0.25	-0.56	-0.06
Cash And Equivalents	-0.14	-0.17	-0.13	-0.54	-0.04	-0.08	0.02	-0.09	0.05	-0.16	-0.41	0.1	-0.28	-0.08	-0.27	0.56	-0.17	-0.23	-0.51	0.21	-0.56	0.66	0.07	-0.28		0.11	0.01	0.14
Net Invested Capital	0.45	0.28	0.62	0.46	-0.04	0.45	-0.03	0.18	0.56	0.35	0.58	-0.23	0.15	0.61	0.3	-0.3	-0.52	0.58	0.3	0.77	0.42	-0.35	0.13	0.25	0.11		-0.67	-0.31
Net Working Capital	-0.36	0.01	-0.7	-0.41	0.16	-0.42	0.33	-0.45	-0.49	-0.15	-0.38	0.55	-0.15	-0.61	-0.24	0.32	0.05	-0.34	-0.32	-0.58	-0.36	0.31	-0.33	-0.56	0.01	-0.67		0.49
Capital Stock	-0.4	0.2	-0.59	-0.47	0.16	-0.42	0.2	0.15	-0.42	0.08	-0.51	0.29	-0.17	-0.62	0.07	0.33	0.08	-0.58	-0.37	-0.19	-0.38	0.41	-0.16	-0.06	0.14	-0.31	0.49

Click cells to compare fundamentals

Pfizer Book Value Per Share Historical Pattern

Today, most investors in Pfizer Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pfizer's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's book value per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Pfizer book value per share as a starting point in their analysis.

Pfizer Book Value Per Share

Timeline

The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

Competition

Predict Pfizer

Book Value Per Share Over Time

Pfizer Common Stock Shares Outstanding

Common Stock Shares Outstanding

6.3 Billion

At present, Pfizer's Common Stock Shares Outstanding is projected to decrease significantly based on the last few years of reporting.

In accordance with the recently published financial statements, the book value per share of Pfizer Inc is about 15.766 times. This is 1027.41% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The book value per share for all United States stocks is 99.18% higher than that of the company.

Pfizer Book Value Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pfizer's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pfizer could also be used in its relative valuation, which is a method of valuing Pfizer by comparing valuation metrics of similar companies.

Pfizer is currently under evaluation in book value per share category among related companies.

Pfizer ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pfizer's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pfizer's managers, analysts, and investors.

Environment Score

Governance Score

Social Score

Pfizer Fundamentals

	Return On Equity	0.0235
	Return On Asset	0.0155
	Profit Margin	0.04 %
	Operating Margin	(0.50) %
	Current Valuation	204.59 B
	Shares Outstanding	5.66 B
	Shares Owned By Insiders	0.04 %
	Shares Owned By Institutions	69.93 %
	Number Of Shares Shorted	65 M
	Price To Earning	9.48 X
	Price To Book	1.65 X
	Price To Sales	2.50 X
	Revenue	58.5 B
	Gross Profit	66.23 B
	EBITDA	10.53 B
	Net Income	2.13 B
	Cash And Equivalents	2.85 B
	Cash Per Share	6.44 X
	Total Debt	75.04 B
	Debt To Equity	0.40 %
	Current Ratio	1.59 X
	Book Value Per Share	15.77 X
	Cash Flow From Operations	8.7 B
	Short Ratio	1.40 X
	Earnings Per Share	0.37 X
	Price To Earnings To Growth	0.26 X
	Target Price	31.1
	Number Of Employees	88 K
	Beta	0.57
	Market Capitalization	146.43 B
	Total Asset	226.5 B
	Retained Earnings	118.35 B
	Working Capital	(4.46 B)
	Current Asset	43.8 B
	Current Liabilities	29.4 B
	Annual Yield	0.07 %
	Five Year Return	3.60 %
	Net Asset	226.5 B
	Last Dividend Paid	1.64

About Pfizer Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Pfizer Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:

How To Invest In Pfizer

Details

Is Pfizer Stock a good investment?

Details

What is Pfizer's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Pfizer Piotroski F Score and Pfizer Altman Z Score analysis.

Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Complementary Tools for Pfizer Stock analysis

When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.

	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Bonds Directory Find actively traded corporate debentures issued by US companies
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Transaction History View history of all your transactions and understand their impact on performance
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets

Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.76)

Dividend Share

1.64

Earnings Share

0.37

Revenue Per Share

10.366

Quarterly Revenue Growth

(0.41)

The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pfizer Inc Stock Book Value Per Share

Pfizer Inc Company Book Value Per Share Analysis

Book Value per Share

Common Equity

Average Shares

Current Pfizer Book Value Per Share

Pfizer Book Value Per Share Driver Correlations

Pfizer Book Value Per Share Historical Pattern

Pfizer Common Stock Shares Outstanding

Common Stock Shares Outstanding

6.3 Billion

Pfizer Book Value Per Share Peer Comparison

Pfizer ESG Sustainability

Pfizer Fundamentals

About Pfizer Fundamental Analysis

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Complementary Tools for Pfizer Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY